BioInvent to Participate in Upcoming Investor Conferences
LUND, SE / ACCESS Newswire / April 1, 2025 /BioInvent International AB("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that during April, the Company management team will participate in the following upcoming investor conferences:
Van Lanschot Kempen Life Sciences Conference
Format: One-on-one meetings
Date: April 2
Location: Amsterdam, The Netherlands
Stifel Virtual Targeted Oncology Forum
Format: Corporate presentation and one-on-one meetings
Date: April 8-9. Corporate presentation April 9 at 11:30 am EDT (Track 2)
Location: Virtual
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company 's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company 's own clinical development pipeline and providing licensing and partnering opportunities.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company 's fully integrated manufacturing unit. More information is available at www.bioinvent.com .
For further information, please contact:
Cecilia Hofvander, VP Investor Relations
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No.: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
Attachments
BioInvent to Participate in Upcoming Investor Conferences
SOURCE: BioInvent International
View the original press release on ACCESS Newswire
© 2025 ACCESS Newswire. All Rights Reserved.
